Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01409434 · ClinicalTrials.gov registry record · Phase 4

Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study

A Phase 4 study, sponsored by University of Florida.

Completed
Registry status
Phase 4
Development phase
44
Enrollment target

NCT01409434: Completed Phase 4 study, sponsored by University of Florida.

NCT01409434 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 44 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01409434, a Phase 4 study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 4
Development phase
44 participants
Enrollment target

Study Summary

This is a research study of the long term effects on blood sugar and cholesterol of blood pressure lowering medications. People are invited to participate in this research study if they participated in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR 1, NCT00246519 or PEAR 2, NCT01203852) study and are still taking a thiazide diuretic. In PEAR, the effects on blood pressure, blood sugar, and cholesterol of the high blood pressure drugs hydrochlorothiazide and atenolol over an 18 week period were evaluated. This PEAR follow-up study will determine the effects of thiazide diuretics on blood sugar and cholesterol, but in the period since the PEAR trial. The study hypothesis is that long term exposure to thiazide diuretics results in larger increases in blood sugar and cholesterol levels than short term exposure.

Interventions

  • DRUG Oral Glucose Tolerance Test

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2010-06
Est. Completion 2013-08
Phase Phase 4
University of Florida

1,106 total trials

What the finished NCT01409434 record still lists

NCT01409434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Oral Glucose Tolerance Test is the first listed.

NCT01409434 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01409434 about?

NCT01409434 is a clinical study titled "Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study". This is a research study of the long term effects on blood sugar and cholesterol of blood pressure lowering medications. People are invited to participate in this research study if they participated in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR 1, NCT00246519 or PEAR 2, NCT01...

What is the current status of trial NCT01409434?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2010-06. Estimated completion is 2013-08.

What interventions are being tested in trial NCT01409434?

The interventions under investigation include: Oral Glucose Tolerance Test (DRUG).

Who is sponsoring clinical trial NCT01409434?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01409434's enrollment target sits among peer trials

44 1363rd of 2000 higher than 630 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01409434, the US trial registry maintained by the National Library of Medicine. NCT01409434 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.